Imidazopyridine

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Imidazo[1,2-a]pyridine—an example of imidazopyridine and a core structure of zolpidem and some compounds described below.
Imidazo[1,2-a]pyridine—an example of imidazopyridine and a core structure of zolpidem and some compounds described below.

An imidazopyridine is a nitrogen containing heterocycle that is also a class of drugs that contain this same chemical substructure. In general, they are GABAA receptor agonists, however recently proton pump inhibitors, aromatase inhibitors, NSAIDs and other classes of drugs in this class have been developed as well. Despite usually being similar to them in effect, they are not chemically related to benzodiazepines. As such, GABAA-agonizing imidazopyridines, pyrazolopyrimidines, and cyclopyrrones are sometimes grouped together and referred to as "nonbenzodiazepines." Imidazopyridines include:

Sedatives[edit]

Anxiolytics, sedatives and hypnotics (GABAA receptor positive allosteric modulators):

Antipsychotic[edit]

Antipsychotics:

  • Imidazo[1,2-a]pyridines:
    • Mosapramine (brand name クレミン, Cremin)—an atypical antipsychotic used in Japan.[3]

Gastrointestinal[edit]

Drugs used for peptic ulcer disease (PUD), GERD and gastroprokinetic agents (motility stimulants):

Anti-inflammatories[edit]

NSAIDs, analgesics and antimigraine drugs:

Cardiovascular[edit]

Drugs acting on the cardiovascular system:

Bone[edit]

Drugs for treatment of bone diseases:

Antineoplastic[edit]

Antineoplastic agents:

Antiviral[edit]

Directly-acting antiviral agents:

References[edit]

  1. ^ Wafford KA, van Niel MB, Ma QP, Horridge E, Herd MB, Peden DR, et al. (January 2009). "Novel compounds selectively enhance delta subunit containing GABA A receptors and increase tonic currents in thalamus". Neuropharmacology. 56 (1): 182–9. doi:10.1016/j.neuropharm.2008.08.004. PMID 18762200.
  2. ^ David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9.
  3. ^ Takahashi N, Terao T, Oga T, Okada M (1999). "Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia". Neuropsychobiology. 39 (2): 81–5. doi:10.1159/000026565. PMID 10072664.
  4. ^ Mikami T, Ochi Y, Suzuki K, Saito T, Sugie Y, Sakakibara M (April 2008). "5-Amino-6-chloro-N-[(1-isobutylpiperidin-4-yl)methyl]-2-methylimidazo[1,2-alpha]pyridine-8-carboxamide (CJ-033,466), a novel and selective 5-hydroxytryptamine4 receptor partial agonist: pharmacological profile in vitro and gastroprokinetic effect in conscious dogs". The Journal of Pharmacology and Experimental Therapeutics. 325 (1): 190–9. doi:10.1124/jpet.107.133850. PMID 18198343.
  5. ^ Belohlavek D, Malfertheiner P (1979). "The effect of zolimidine, imidazopyridine-derivate, on the duodenal ulcer healing". Scandinavian Journal of Gastroenterology. Supplement. 54: 44. PMID 161649.
  6. ^ Kahrilas PJ, Dent J, Lauritsen K, Malfertheiner P, Denison H, Franzén S, Hasselgren G (December 2007). "A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis". Clinical Gastroenterology and Hepatology. 5 (12): 1385–91. doi:10.1016/j.cgh.2007.08.014. PMID 17950677.
  7. ^ Ravinder Reddy S, Basavaraja HS, Shivaprasad S. "Reversible Proton Pump Inhibitors: A Superior Edge — Features". Pharmabiz.com. Saffron Media Pvt. Ltd I. Archived from the original on 5 March 2016. Retrieved 7 December 2015.
  8. ^ Merck Announces Second Quarter 2011 Financial Results
  9. ^ Uemura Y, Tanaka S, Ida S, Yuzuriha T (December 1993). "Pharmacokinetic study of loprinone hydrochloride, a new cardiotonic agent, in beagle dogs". The Journal of Pharmacy and Pharmacology. 45 (12): 1077–81. doi:10.1111/j.2042-7158.1993.tb07184.x. PMID 7908977.
  10. ^ Hegde S, Schmidt M (January 2010). "To market, to market—2009". Annual Reports in Medicinal Chemistry. 45: 466–537. doi:10.1016/s0065-7743(10)45028-9.
  11. ^ Hebner CM, Han B, Brendza KM, Nash M, Sulfab M, Tian Y, et al. (2012). "The HCV non-nucleoside inhibitor Tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function". PLOS One. 7 (6): e39163. doi:10.1371/journal.pone.0039163. PMC 3374789. PMID 22720059.